BioOutsource Opens New Facility in Glasgow

News
Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-08-05-2015
Volume 11
Issue 8

The investment doubles the company’s capacity to meet increasing demand for its biologics contract testing and biosimilar characterization services.

BioOutsource, part of Sartorius Stedim Biotech Group, has opened a new facility in Glasgow. The investment follows the increasing demand for the company’s biologics contract testing and biosimilar characterization services. The new facility doubles BioOutsource’s capacity for future growth and will create approximately 50 new jobs for scientific and technical professionals in the next six months, according to the company.

Source: BioOutsource

Articles in this issue
Figures1-New-1438610917643.gif
CDMOs Move Slowly with Expansion Plans
Accelerating Continuous API Synthesis
Accelerating Continuous API Synthesis
BioOutsource Opens New Facility in Glasgow
Needle in the Haystack, or Rembrandt in the Attic? Drug Repurposing's New Strategy
Silicone Rubber Pieces Spur Recall of Teva Product
Baxter Recalls IV Solution for Container and Particulate Issues
Indian API Manufacturer Cited for Recordkeeping Failures
Xcelience Makes Investment in Powdersize
FDA Issues Quality Metrics Draft Guidance Document for Comment
EMA Issues Guideline on Fast Tracking Drugs for Unmet Needs
SafeBridge Updates Potent API and Drug Manufacturer Status
Capsugel Expands Capabilities at its Edinburgh Facility
DPx Holdings Sells Fine Chemicals Business
World Courier Receives UK Wholesale Distribution Authorisation
CSafe Adds Service Center for Controlled-Temperature Shipping in Switzerland
Recent Videos
Behind the Headlines, Episode 17
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Related Content
·Mirai Bio and Thermo Fisher are partnering to integrate design, delivery, and CGMP manufacturing for nucleic acid-based therapeutics. ·The collaboration will leverage Thermo Fisher’s RNA and advanced formulations facility to support scalable development of genetic medicines. ·Mirai’s machine intelligence platform will be combined with Thermo Fisher’s technical and manufacturing expertise to streamline drug development workflows.

Mirai Bio and Thermo Fisher Partner to Advance Genetic Medicine Manufacturing

Christopher Cole
May 21st 2025
Article

Mirai Bio and Thermo Fisher partner to integrate AI-driven design with CGMP manufacturing, aiming to streamline development of genetic medicines.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Abnormal plasma cell or b-cell in multiple myeloma emitting paraprotein 3d illustration | Image Credit: © LASZLO - stock.adobe.com

CellCentric Completes $120 Million Series C Funding Round for Multiple Myeloma Treatment Inobrodib

Patrick Lavery
May 21st 2025
Article

Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only multiple myeloma, but other specific cancers as well.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Coronavirus Covid-19 background - 3d rendering | Image Credit: © Production Perig - stock.adobe.com

EMA Recommends Update to COVID-19 Vaccines for 2025-26 Campaign

Patrick Lavery
May 19th 2025
Article

The LP.8.1 variant of the SARS-CoV-2 virus differs from the JN.1 family that previous vaccines had been designed to target, and has surpassed JN.1 as the variant circulating most widely worldwide.

IRVINE, CALIFORNIA - 16 APRIL 2020: Student Center and Visitor Center Building on the campus of the University of California Irvine, UCI. | Image Credit: © Steve Cukrov - stock.adobe.com

UC Irvine Lab Studies NLRP3 Inflammasome for Inflammatory Disease Treatment Potential

Patrick Lavery
May 19th 2025
Article

Researchers say they have discovered the first drug mechanism that binds to the pyrin domain to block NLRP3 and prevent a series of reactions resulting in inflammation.